The factor that leads to coexistence of hyperinsulinemia (high insulin) and hyperglycemia (high blood sugar) is insulin resistance. In this condition, your cells stop responding normally to insulin, so your pancreas pumps out more and more insulin to compensate, yet blood sugar remains elevated because the extra insulin can’t do its job effectively. This paradox sits at the center of type 2 diabetes, metabolic syndrome, and several other chronic conditions.
How Insulin Resistance Creates the Paradox
Under normal circumstances, when blood sugar rises after a meal, your pancreas releases insulin. That insulin signals muscle, fat, and liver cells to absorb glucose from the bloodstream. Blood sugar drops, and insulin levels fall back down. The system stays in balance.
When cells become resistant to insulin, this feedback loop breaks. Muscle and fat cells don’t take up glucose efficiently, so blood sugar stays high. Your pancreas detects the persistent high glucose and responds by secreting even more insulin. The result: both insulin and blood sugar are elevated at the same time. This is the prediabetic state, and it can persist for years before a formal diabetes diagnosis. Insulin resistance precedes abnormal blood sugar levels, meaning your insulin is already running high before glucose readings start to look concerning on a standard blood test.
What Goes Wrong Inside the Cell
Insulin works by binding to a receptor on the cell surface, triggering a chain of internal signals that ultimately moves glucose transporters (called GLUT4) to the cell membrane. Think of GLUT4 as a door that opens to let sugar in. In insulin-resistant cells, several links in this signaling chain malfunction.
The receptor itself may have reduced activity. In people with obesity and diabetes, the receptor’s ability to kick off its signaling cascade is diminished in skeletal muscle. Downstream from the receptor, key relay molecules get blocked. One major disruption involves a specific signaling enzyme (a form of Akt called Akt2) that is primarily responsible for moving GLUT4 to the cell surface. When chronic high insulin impairs Akt2 activity, GLUT4 transporters stay trapped inside the cell. Glucose piles up in the bloodstream even though insulin is knocking on the door.
Research in fat cells has shown that chronic hyperinsulinemia itself worsens this problem, creating a vicious cycle. Prolonged high insulin impairs the very signaling pathway that insulin uses to move glucose transporters, while other insulin-driven processes (like suppressing certain genes) may still partially function. This selective resistance means insulin loses its ability to clear sugar from the blood while retaining some of its other effects on the body.
The Liver Keeps Making Sugar
Your liver is a major source of blood glucose. Between meals, it produces sugar through a process called gluconeogenesis. Normally, insulin after a meal shuts this process down. In healthy people, a rise in insulin suppresses liver glucose production by about 20% on top of completely halting the breakdown of stored glycogen.
In insulin resistance, this brake fails. Insulin can no longer deactivate a key protein (FOXO1) that drives glucose production in liver cells. So the liver keeps churning out sugar even after you’ve eaten, when blood sugar is already high and insulin is already elevated. This adds fuel to the fire: you now have high blood sugar coming from two sources, the food you ate and your own liver, with insulin unable to stop either one effectively.
How Fat Drives the Process
Excess body fat, particularly around the organs, is one of the strongest drivers of insulin resistance. The connection goes beyond simply carrying extra weight. Fat tissue releases free fatty acids into the bloodstream, and elevated levels of these fats directly interfere with insulin signaling inside muscle and liver cells.
Here’s how it works: when free fatty acids accumulate inside muscle cells, they get converted into a fat byproduct called diacylglycerol (DAG). DAG activates an enzyme that disrupts the insulin signaling chain by altering how relay molecules get switched on. Specifically, it causes these molecules to receive the wrong type of activation signal, effectively jamming the pathway. The same process occurs in liver cells, contributing to the liver’s failure to stop producing glucose.
Free fatty acids also trigger inflammatory signaling. They activate pathways that produce inflammatory molecules, which further impair insulin’s ability to communicate with cells. This creates an environment where fat accumulation, inflammation, and insulin resistance reinforce each other continuously.
Inflammation as a Compounding Factor
Chronic low-grade inflammation plays a direct role in sustaining insulin resistance. Fat tissue in people with obesity doesn’t just store energy; it acts as an active source of inflammatory signals. One of the most studied is a molecule called TNF-alpha, which immune cells in fat tissue produce in elevated amounts.
TNF-alpha strongly inhibits insulin-stimulated glucose uptake in fat cells. It does this by interfering with the insulin receptor itself, reducing the receptor’s ability to activate and pass its signal forward. The effect on the next step in the chain is even more dramatic: TNF-alpha causes a sharp drop in the activation of the receptor’s main internal target. The insulin receptor isolated from cells exposed to TNF-alpha is functionally defective, unable to properly relay insulin’s message even in laboratory conditions. This means inflammation doesn’t just make insulin resistance worse at the whole-body level; it physically damages the signaling machinery inside individual cells.
The Pancreas Eventually Loses the Battle
For a time, the pancreas can keep up. Beta cells (the insulin-producing cells) compensate for resistance by growing in both size and number, a process called hypertrophy and hyperplasia. This is why insulin levels climb so high in the early stages. The pancreas is working overtime to force enough insulin into the bloodstream to maintain near-normal blood sugar.
This compensation can last years, but it has a limit. Over time, the constant demand exhausts beta cells. The rate of beta cell death begins to exceed the rate of new cell growth, and total beta cell mass declines. A progressive loss of function precedes outright cell death, meaning the cells become less efficient at sensing and responding to glucose before they actually disappear. Eventually, the pancreas can no longer produce enough insulin to overcome the resistance, and blood sugar rises sharply. At this point, the person transitions from prediabetes to type 2 diabetes. In advanced stages, insulin levels may actually start to fall as beta cells fail, shifting from hyperinsulinemia to relative insulin deficiency.
Effects Beyond Blood Sugar
One of the more counterintuitive aspects of insulin resistance is that not all tissues become resistant to all of insulin’s effects at the same rate. The kidneys are a clear example. While muscle and liver cells lose their sensitivity to insulin’s glucose-lowering signal, the kidneys retain or even enhance their response to insulin’s effect on sodium. High insulin levels promote sodium reabsorption in the kidneys, causing the body to hold onto more salt and water. This raises blood pressure. Meanwhile, insulin’s normal ability to relax blood vessels is impaired in insulin-resistant states. The combination of increased sodium retention and reduced blood vessel relaxation helps explain why high blood pressure is so common alongside insulin resistance.
Polycystic ovary syndrome (PCOS) is another condition tightly linked to hyperinsulinemia. Elevated insulin stimulates the ovaries to produce excess androgens (male-type hormones), contributing to irregular periods, acne, and fertility problems. Reducing insulin levels through weight loss and dietary changes often improves PCOS symptoms more effectively than targeting the hormonal imbalance directly.
How Insulin Resistance Is Measured
The most common clinical tool for estimating insulin resistance is HOMA-IR, which uses a simple formula based on fasting insulin and fasting glucose levels. A 2025 study evaluating a large population found an optimal cutoff of 1.878 or higher, with 87% sensitivity and 77% specificity for identifying insulin resistance. This threshold varies by population: studies from different countries have reported cutoffs ranging from 1.6 to over 3.0, reflecting differences in genetics, diet, and body composition. Men tend to have a slightly lower threshold (around 1.7) than women (around 2.0).
HOMA-IR is useful as a screening tool, but it captures a snapshot of fasting conditions. It won’t reveal how your body handles glucose after a meal, which is often where insulin resistance shows up first. More dynamic tests exist but are primarily used in research settings rather than routine clinical practice.